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RENAL TUBULAR DAMAGE AND HYPOMAGNESEMIA
FOLLOWING CDDP COMBINATION CHEMOTHERAPY
Juichi KAwAMuRA， Yoshihito HIGAsHi， Yusaku OKADA，
            Asaki SoEDA and Osamu YosHmA
．From 1’lze DePartment of Urology， Faculty of Medicine， K／oto University
                 （Director： Prof． O． Yoshida）
  Studies on renal function were made on 5 patients with nonseminomatous testicu1ar cancer
who received multiple drug ¢hemotheraphy including aDDP．
  Glbinerular filtration rate （GFR） decreased transiently during each course of chemotherapy
and returned to the pretreatment level during the period of cessation of medication． ln 2
0ut of 5 patients， however， an irreversible decrease． to below 50 ml／min was seen after 4
courseS of chemotherapy． Urinary excretion of P2 microglobulin （P2MG） increased tran－
siently before GFR began to decreqse during each course of chemotherapy． Urinary ex－
cretiOn’Of P2MG persisted at a high level in Patients who showed a prominent decrease in
GFR． Serum magnesium levels gradually decreased． Particularly， after 4 courses of chemo－
therapy，． hypQmagnesemia was evident in 4 ．patients． One of them complained of neuromus－
cular disturbance in the f6ur extremities． Urinary excretion of magnesium markedly increased
during the’@diufetic ph．ase． of the period of CDDP adminiStration ahd the amount of
magnesiurri wds less than 10 mEq／day without supplemgnt of magnesium loss． Hbwever，
serum magnesium levels tended to be’ low’@in the case of low．e；ed rena｝ function’ even when
magnesium was supplied intravenously． Serum calcium levels decreased transiently but
there was no relationship between hypocalcemia and hypomagnecernia． Sefum sodium， potas－
sium and parathyroid hormone levels remained normal through 4 courses of chemotherapy．
  In conclusion， intermittent adminisitration of ’CDDP （in ．total dose more than 600 mg）
induced dose－dependent renal tubular damage， which caused a decrease in GFR， increase
in urinary excretion of P2MG and urinary leakage of Magnesium． The severity of hypo－
magnesernia paralleled the impairment of renal function． Therefore， it is suggested that a
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  subtle renal tubular dysfunction of patients receiving CDDP－treatment should be monitored
  regularly．
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 化学療法のレジメはCDDP 20 mg／m2， iv．5日
掛ab互e 1．Hypomagnesgmia in 5 patients with non－seminOmatous germ cell tumor









U．ripar．y Excrgtion of B 2Micro－
globulin， maximum
（Normal Range：133－47） （μg／day）
Serum Magnesium， nadir （mg／d2）
Duration of Hypomagnesemia （day）
Cumurative Cisplatinum Dose’to
Onset of Hypomagnesemia （mg）
Time ．to Onset of Hypomagnesemia
（d4Y）
















































間，3週毎，b1comycin 30 mg／週， iv．12週， vinbla－
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． Creatinine clearance through 4 courses
  of CDDP chemotherapy in 5 patients
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Urinary excretion of P2microglobulin
through 4 courses of CDDP chemo－
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Serum magnesium， calcium and potas－
slum concentrations through 4 courses
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Fig． 4． Alterations in creatinine clearance， serum and urinary magnesium concentrations
    through 4 courses of CDDP chemotherapy in case N． H．． （ ） indicates urinary
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